Molecular mechanism of 7TM receptor activation - A global toggle switch model

Annual Review of Pharmacology and Toxicology

Volumn 46, Issue , 2006, Pages 481-519

  Schwartz, Thue W ^a   Frimurer, Thomas M ^a   Holst, Birgitte ^a   Rosenkilde, Mette M ^a   Elling, Christian E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Agonist binding; Allosteric mechanism; Antagonism; G protein coupled receptors; Rhodopsin like receptors

Indexed keywords

ANGIOTENSIN I; DISULFIDE; G PROTEIN COUPLED RECEPTOR; LIGAND; METAL ION; PEPTIDE; PROLINE; RHODOPSIN; SUBSTANCE P;

ALLOSTERISM; BINDING SITE; BIOPHYSICS; CONFORMATIONAL TRANSITION; DISULFIDE BOND; GLOBAL TOGGLE SWITCH MODEL; LIGAND BINDING; MOLECULAR MODEL; MOTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR OCCUPANCY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; CYTOPLASM; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTOR, MUSCARINIC M2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 33144459843     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.46.120604.141218     Document Type: Review

References (186)

1. Bockaert J, Pin JP. 1999. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 18:1723-29
2. Schwartz TW, Holst B. 2002. Molecular structure and function of 7TM/G-protein coupled receptors. In Textbook of Receptor Pharmacology, ed. JC Forman, T Johansen, pp. 65-84. Boca Raton, FL: CRC Press
3. Lefkowitz RJ. 2004. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25:413-22
4. Gether U. 2000. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors Endocr. Rev. 21:90-113
5. Klabunde T, Hessler G. 2002. Drug de-sign strategies for targeting G-protein-coupled receptors. Chembiochemistry 3:928-44
6. Evers A, Klabunde T. 2005. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 48:1088-97
7. Frimurer TM, Ulven T, Elling CE, Gerlach LO, Kostenis E, Hogberg T. 2005. A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg. Med. Chem. Lett. 15:3707-12
8. Buck E, Wells JA. 2005. Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 102:2719-24
9. Erlanson DA, Wells JA, Braisted AC. 2004. Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33:199-223
10. Crossley R. 2004. The design of screening libraries targeted at G-protein coupled receptors. Curr. Top. Med. Chem. 4:581-88
11. Kenakin T. 2001. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15:598-611
12. Holst B, Hastrup H, Raffetseder U, Martini L, Schwartz TW. 2001. Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. J. Biol. Chem. 276:19793-99
13. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-45
14. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. 2004. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 343:1409-38
15. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. 2004. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J. Mol. Biol. 342:571-83
16. Gether U, Lin S, Kobilka BK. 1995. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-epscific conformational changes. J. Biol. Chem. 270:28268-75
17. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. 1996. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274:768-70
18. Sheikh SP, Zvyaga TA, Lichtarge O, Sakmar TP, Bourne HR. 1996. Rhodopsin activation blocked by metalion-binding sites linking transmembrane helices C and F. Nature 383:347-50
19. Altenbach C, Yang K, Farrens DL, Farahbakhsh ZT, Khorana HG, Hubbell WL. 1996. Structural features and light dependent changes in the cytoplasmic interhelical E-F- loop region of Rhodopsin: a site-directed spin-labeling study. Biochemistry 35:12470-78
20. Gether U, Lin S, Ghanouni P, Ballesteros JA, Weinstein H, Kobilka BK. 1997. Agonist induced conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor. EMBO J. 16:6737-47
21. Javitch JA, Fu D, Liapakis G, Chen J. 1997. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J. Biol. Chem. 272:18546-49
22. Hubbell WL, Altenbach C, Hubbell CM, Khorana HG. 2003. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 63:243-90
23. Fritze O, Filipek S, Kuksa V, Palczewski K, Hofmann KP, Ernst OP. 2003. Role of the conserved NPxxY(x)5, 6F motif in the rhodopsin ground state and during activation. Proc. Natl, Acad. Sci. USA 100:2290-95
24. Krishna AG, Menon ST, Terry TJ, Sakmar TP. 2002. Evidence that helix 8 of rhodopsin acts as a membrane-dependent conformational switch. Biochemistry 41:8298-309
25. Elling CE, Thirstrup K, Holst B, Schwartz TW. 1999. Conversion of agonist site to metal-ion chelator site in the beta(2)- adrenergic receptor. Proc. Natl. Acad. Sci. USA 96:12322-27
26. Holst B, Elling CE, Schwartz TW. 2000. Partial agonism through a zincion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. Mol. Pharmacol. 58:263-70
27. Elling CE, Frimurer TM, Gerlach LO, Joørgensen R, Holst B, Schwartz TW. 2005. A global toggle switch activation mechanism for 7TM receptors-dissected through metal-ion site engineering. J. Mol. Biol. Submitted
28. Schwartz TW, Gether U, Schambye HT, Hjorth SA. 1995. Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr. Pharmaceut. Design 1:325-42
29. Schwartz TW, Rosenkilde MM. 1996. Is there a 'lock' for all 'keys' in 7TM receptors. Trends Pharmacol. Sci. 17:213-16
30. Ruprecht JJ, Mielke T, Vogel R, Villa C, Schertler GF. 2004. Electron crystallography reveals the structure of metarhodopsin I. EMBO J. 23:3609-20
31. Krebs A, Edwards PC, Villa C, Li J, Schertler GF. 2003. The three-dimensional structure of bovine rhodopsin determined by electron cryomicroscopy. J. Biol. Chem. 278:50217-25
32. Baldwin JM, Schertler GFX, Unger VM. 1997. An alpha-carbon template for the transmembrane helices in rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 272:144-64
33. Unger VM, Schertler GFX. 1995. Low resolution structure of bovine rhodopsin determined by electron cryomicroscopy, Biophys. J. 68:1776-86
34. Unger VM, Hargrave PA, Baldwin JM, Schertler GFX. 1997. Arrangement of rhodopsin transmembrane alpha-helices. Nature 389:203-6
35. Ballesteros JA, Shi L, Javitch JA. 2001. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 60:1-19
36. Ballesteros J, Palczewski K. 2001. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discov. Devel. 4:561-74
37. Filipek S, Teller DC, Palczewski K, Stenkamp R. 2003. The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors. Annu. Rev. Biophys. Biomol. Struct. 32:375-97
38. Stenkamp RE, Teller DC, Palczewski K. 2005. Rhodopsin: a structural primer for G-protein coupled receptors. Arch. Pharm. (Weinheim) 338:209-16
39. Okada T, Ernst OP, Palczewski K, Hofmann KP. 2001. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem. Sci. 26:318-24
40. Okada T. 2004. X-ray crystallographic studies for ligand-protein interaction changes in rhodopsin. Biochem. Soc. Trans. 32:738-41
41. Lu ZL, Saldanha JW, Hulme EC. 2002. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 23:140-46
42. Meng EC, Bourne HR. 2001. Receptor activation: what does the rhodopsin structure tell us? Trends Pharmacol. Sci. 22:587-93
43. Bourne HR, Meng EC. 2000. Structure. Rhodopsin sees the light. Science 289:733-34
44. Silvente-Poirot S, Escrieut C, Wank SA. 1998. Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol. Pharmacol. 54:364-71
45. Shi L, Javitch JA. 2004. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc. Natl. Acad. Sci. USA 101:440-45
46. Strader CD, CandeloreMR, Hill WS, Sigal IS, Dixon RAF. 1989. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264:13572-78
47. Strader CD, Sigal IS, Candelore MR, Rands E, Hill WS, Dixon RAF. 1988. Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263:10267-71
48. Strader CD, Sigal IS, Register RB, Candelore MR, Rands E, Dixon RAF. 1987. Identification of residues required for ligand binding to the β-adrenergic receptor. Proc. Natl. Acad. Sci. USA 84:4384-88
49. Dixon RAF, Sigal IS, Rands E, Register RB, Candelore MR, et al. 1987. Ligand binding to the β-adrenergic receptor involves its rhodopsin-like core. Nature 326:73-77
50. Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ. 1988. Chimeric α2, β2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 240:1310-16
51. Strader CD, Gaffney T, Sugg EE, Candelore MR, Keys R, et al. 1991. Allele-specific activation of genetically engineered receptors. J. Biol. Chem. 266:5-8
52. Wieland K, Zuurmond HM, Krasel C, Ijzerman AP, Lohse MJ. 1996. Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta2-adrenergic receptor. Proc. Natl. Acad. Sci. USA 93:9276-81
53. Wang C-D, Buck MA, Fraser CM. 1991. Site-directed mutagenesis of α2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol. Pharm. 40:168-79
54. Marullo S, Ernenne LJ, Strosberg AD, Delavier-Klutchko C. 1990. Selective binding of ligands to β1, β2 or chimeric β1/β2-adrenergic receptors involves multiple subsites. EMBO J. 9:1471-76
55. Frielle T, Daniel K, Caron MG, Lefkowitz RJ. 1988. Structural basis of β-adrenergic receptor subtype specificity studied with chimeric β1/β2-adrenergic receptors. Proc. Natl. Acad. Sci. USA 85:9494-98
56. Page KM, Curtis CA, Jones PG, Hulme EC. 1995. The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. Eur. J. Pharmacol. 289:429-37
57. Hulme EC, Lu ZL, Bee M, Curtis CA, Saldanha J. 2001. The conformational switch in muscarinic acetylcholine receptors. Life Sci. 68:2495-500
58. Naylor L, Woodward R, Daniell S, Coley C, Strange PG. 1995. Determinants of ligand binding of the D2 dopamine receptor. Biochem. Soc. Trans. 23:87-91
59. Mansour A, Meng F, Meador-Woodruff JH, Taylor LP, Civelli O, Akil H. 1992. Site-directed mutagenesis of the human dopamine D2 receptor. Eur. J. Pharm. 227:205-14
60. Javitch JA. 1998. Mapping the binding-site crevice of the D2 receptor. Adv. Pharmacol 42:412-15
61. Rao VR, Cohen GB, Oprian DD. 1994. Rhodopsin mutation G90D and a molecular mechanism for congenital night blindness. Nature 367:639-42
62. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD. 1992. Constitutively active mutants of rhodopsin. Neuron 8:719-25
63. Shieh T, Han M, Sakmar TP, Smith SO. 1997. The steric trigger in rhodopsin activation. J. Mol. Bio. 269:373-84
64. Baldwin JM. 1993. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12:1693-703
65. Schwartz TW. 1994. Locating ligand-binding sites in 7TM receptors by protein engineering. Curr. Opin. Biotech. 5:434-44
66. Ballesteros JA, Weinstein H. 1995. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Receptor Molecular Biology, ed. SC Sealfon, pp. 366-428. New York: Academic
67. Gether U, Nilsson L, Lowe JA III, Schwartz TW. 1994. Specific residues at the top of transmembrane segment V and VI of the neurokinin-1 receptor involved in binding of the nonpeptide antagonist CP96,345. J. Biol. Chem. 269:23959-64
68. Gether U, Johansen TE, Snider RM, Lowe JA III, Nakanishi S, Schwartz TW. 1993. Different binding epitopes on the NK1 receptor for substance P and a non-peptide antagonist. Nature 362:345-48
69. Gether U, Yokota Y, Emonds-Alt X, Breliére JC, Lowe JA III, et al. 1993. Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors. Proc. Nad. Acad. Sci. USA 90:6194-98
70. Huang RC, Yu H, Strader CD, Fong TM. 1994. Localization of the ligand binding site of the neurokinin-1 receptor: interpretation of chimeric mutations and single-residue substitutions. Mol. Pharmacol. 45:690-95
71. Fong TM, Cascieri MA, Yu H, Bansal A, Swain C, Strader CD. 1993. Aminoaromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. Nature 362:350-53
72. Fong TM, Huang RC, Stader CD. 1992. Localization of agonist and antagonist binding domains of the human neurokinin-1 receptor. J. Biol. Chem. 267:25664-67
73. Fong TM, Yu H, Huang RC, Stader CD. 1992. The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides. Biochemistry 31:11806-11
74. Schambye HT, Hjorth SA, Bergsma DJ, Sathe G, Schwartz TW. 1994. Differentiation between binding sites for angiotensin II and non-peptide antagonists on the AT1 receptors. Proc. Natl. Acad. Sci. USA 91:7046-50
75. Hjorth SA, Schambye HT, Greenlee WJ, Schwartz TW. 1994. Identification of peptide binding residues in the extracellular domains of the AT1 receptor. J. Biol. Chem. 269:30953-59
76. Schambye HT, Wijk BV, Hjorth SA, Wienen W, Entzeroth M, et al. 1994. Mutations in transmembrane segmant VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists. Br. J. Pharmacol. 113:331-33
77. 1A angiotensin II receptor is essential for its coupling to phospholipase C. J. Biol. Chem. 269:20815-18
78. Yamano Y, Ohyama K, Chaki S, Guo D-F, Inagami T. 1992. Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis. Biochem. Biophys. Res. Comm. 187:1426-31
79. Monod J, Wyman J, Changeux J-P. 1965. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12:88-118
80. Hubbell WL, Cafiso DS, Altenbach C. 2000. Identifying conformational changes with site-directed spin labeling. Nat. Struct. Biol. 7:735-39
81. Hubbell WL, Gross A, Langen R, Lietzow MA. 1998. Recent advances in site-directed spin labeling of proteins. Curr. Opin. Struct. Biol. 8:649-56
82. Hubbell WL, Mchaourab HS, Altenbach C, Lietzow MA. 1996. Watching proteins move using site-directed spin labeling. Structure 4:779-83
83. Farahbakhsh ZT, Altenbach C, Hubbell WL. 1992. Spin labeled cysteines as sensors for protein-lipid interaction and conformation in rhodopsin. Photochem. Photobiol. 56:1019-33
84. Altenbach C, Cai K, Klein-Seetharaman J, Khorana HG, Hubbell WL. 2001. Structure and function in rhodopsin: mapping light-dependent changes in distance between residue 65 in helix TM1 and residues in the sequence 306-319 at the cytoplasmic end of helix TM7 and in helix H8. Biochemistry 40:15483-92
85. Cai K, Klein-Seetharaman J, Farrens D, Zhang C, Altenbach C, et al. 1999. Single-cysteine substitution mutants at amino acid positions 306-321 in rhodopsin, the sequence between the cytoplasmic end of helix VII and the palmitoylatiori sites: sulfhydryl reactivity and transducin activation reveal a tertiary structure. Biochemistry 38:7925-30
86. Altenbach C, Cai K, Khorana HG, Hubbell WL. 1999. Structural features and light-dependent changes in the sequence 306-322 extending from helix VII to the palmitoylation sites in rhodopsin: a site-directed spin-labeling study. Biochemistry 38:7931-37
87. Altenbach C, Klein-Seetharaman J, Hwa J, Khorana HG, Hubbell WL. 1999. Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study. Biochemistry 38:7945-19
88. Langen R, Cai K, Altenbach C, Khorana HG, Hubbell WL. 1999. Structural features of the C-terminal domain of bovine rhodopsin: a site-directed spin-labeling study. Biochemistry 38:7918-24
89. Kim JM, Altenbach C, Thurmond RL, Khorana HG, Hubbell WL. 1997. Structure and function in rhodopsin: rhodopsin mutants with a neutral amino acid at E134 have a partially activated conformation in the dark state. Proc. Natl. Acad. Sci. USA 94:14273-78
90. Cai K, Langen R, Hubbell WL, Khorana HG. 1997. Structure and function in rhodopsin: topology of the C-terminal polypeptide chain in relation to the cytoplasmic loops Proc. Natl. Acad. Sci. USA 94:14267-72
91. Farahbakhsh ZT, Ridge KD, Khorana HG, Hubbell WL. 1995. Mapping light-dependent structural changes in the cytoplasmic loop connecting Helices C and D in rhodopsin: a site-directed spin labeling study. Biochemistry 34:8812-19
92. Farahbakhsh ZT, Hideg K, Hubbell WL. 1993. Photoactivated conformational changes in rhodopsin: a time-resolved spin label study. Science 262:1416-19
93. Patel AB, Crocker E, Reeves PJ, Getmanova EV, Eilers M, et al. 2005. Changes in interhelical hydrogen bonding upon rhodopsin activation. J. Mol. Biol. 347:803-12
94. Patel AB, Crocker E, Eilers M, Hirshfeld A, Sheves M, Smith SO. 2004. Coupling of retinal isomerization to the activation of rhodopsin. Proc. Natl. Acad. Sci. USA 101:10048-53
95. Cai K, Klein-Seetharaman J, Altenbach C, Hubbell WL, Khorana HG. 2001. Probing the dark state tertiary structure in the cytoplasmic domain of rhodopsin: proximities between amino acids deduced from spontaneous disulfide bond formation between cysteine pairs engineered in cytoplasmic loops 1,3, and 4. Biochemistry 40:12479-85
96. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, Kobilka BK. 1997. Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J. Biol. Chem. 272:2587-90
97. Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, Gether U. 2001. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem. 276:9279-90
98. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK. 2001. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc. Natl. Acad. Sci. USA 98:5997-6002
99. Dunham TD, Farrens DL. 1999. Conformational changes in rhodopsin. Movement of helix f detected by site-specific chemical labeling and fluorescence spectroscopy. J. Biol. Chem. 274:1683-90
100. Cai K, Klein-Seetharaman J, Hwa J, Hubbell WL, Khorana HG. 1999. Structure and function in rhodopsin: effects of disulfide cross-links in the cytoplasmic face of rhodopsin on transducin activation and phosphorylation by rhodopsin kinase. Biochemistry 38:12893-98
101. 2- adrenoceptor and the parathyoid hormone receptor. J. Biol. Chem. 274:17033-41
102. Lin SW, Sakmar TP. 1996. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35:11149-59
103. Elling CE, Raffetseder U, Nielsen SM, Schwartz TW. 2000. Bisulfide bridge engineering in the tachykinin NK1 receptor. Biochemistry 39:667-75
104. Erlenbach I, Kostenis E, Schmidt C, Serradeil-Le Gal C, Raufaste D, et al. 2001. Single amino acid substitutions and deletions that alter the G protein coupling properties of the V2 vasopressin receptor identified in yeast by receptor random mutagenesis. J. Biol. Chem. 276:29382-92
105. Wess J. 1998. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol. Ther. 80:231-64
106. Franke RR, Konig B, Sakmar TP, Khorana HG, Hofmann KP. 1990. Rhodopsin mutants that bind but fail to activate transducin. Science 250:123-25
107. Prioleau C, Visiers I, Ebersole BJ, Weinstein H, Sealfon SC. 2002. Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. J. Biol. Chem. 277:36577-84
108. Fanelli F, De Benedetti PG. 2005. Computational modeling approaches to structure-function analysis of g protein-coupled receptors. Chem. Rev. 105:3297-351
109. Elling CE, Nielsen SM, Schwartz TW. 1995. Conversion of antagonist-binding site to metal-ion site in the tachykinin Nk-1 receptor. Nature 374:74-77
110. Elling CE, Thirstrup K, Nielsen SM, Hjorth SA, Schwartz TW. 1997. Engineering of metal-ion sites as distance constraints in structural and functional analysis of 7TM receptors. Fold. Design 2:S76-80
111. Thirstrup K, Elling CE, Hjorth SA, Schwartz TW. 1996. Construction of a high affinity zinc-switch in the kopioid receptor. J. Biol. Chem. 271:7875-78
112. Elling CE, Schwartz TW. 1996. Connectivity and orientation of the seven helical bundle in the tachykinin NK-1 receptor probed by zinc site engineering. EMBO J. 15:6213-19
113. Yu H, Kono M, McKee TD, Oprian DD. 1996. A general method for mapping tertiary contacts between amino acid residues in membrane-embedded proteins. Biochemistry 34(46):14963-68
114. Strader CD, Sigal IS, Dixon RAF. 1989. Structural basis of β-adrenergic receptor function. FASEB J. 3:1825-32
115. Dixon RAF, Sigal IS, Strader CD. 1988. Structure-function analysis of the β-adrenergic receptor. Cold Spring Harbor Symp. Quant. Biol. LML:487-97
116. Holst B, Zoffmann S, Elling CE, Hjorth SA, Schwartz TW. 1998. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. Mol. Pharm. 53:166-75
117. Nilsson I, Saaf A, Whitley P, Gafvelin G, Waller C, von Heijne G. 1998. Proline-induced disruption of a transmembrane alpha-helix in its natural environment. J. Mol. Biol. 284:1165-75
118. von Heijne G. 1991. Proline kinks in transmembrane alpha-helices. J. Mol. Biol. 218:499-503
119. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. 2002. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277:40989-96
120. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, et al. 2001. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 276:29171-77
121. Sansom MS, Weinstein H. 2000. Hinges, swivels and switches: the role of prolines in signalling via transmembrane alphahelices. Trends Pharmacol. Sci. 21:445-51
122. Mirzadegan T, Benko G, Filipek S, Palczewski K. 2003. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42:2759-67
123. Holst B, Bach A, Howard A, Frimurer TM, Schwartz TW. 2005. 7TM receptor activation mechanism - PheV:13 as a conserved lock for the TrpVI:13 activation switch. J. Biol. Chem. Submitted
124. Javitch JA, Fu D, Chen J. 1995. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. Biochemistry 34:16439
125. Javitch JA, Shi L, Liapakis G. 2002. Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors. Methods Enzymol. 343:137-56
126. Glusker JP. 1991. Structural aspects of metal liganding to functional groups in proteins. Adv. Protein Chem. 42:3-76
127. Chakrabarti P. 1990. Geometry of interaction of metal ions with histidine residues in protein structures. Protein Eng. 4:57-63
128. Rosenkilde MM, Kledal TN, Brauner-Osborne H, Schwartz TW. 1999. Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74.7. Biol. Chem. 274:956-61
129. Rosenkilde MM, Lucibello M, Holst B, Schwartz TW. 1998. Natural agonist enhancing bis-His zinc-site in transmembrane segment V of the tachykinin NK3 receptor. FEBS Lett. 439:35-40
130. Li H, Macdonald DM, Hronowski X, Costello CE, Leeman SE, Boyd ND. 2001. Further definition of the substance P (SP)/neurokinin-1 receptor complex. MET-174 is the site of photoinsertion p-benzoylphenylalanine4 SP. J. Biol. Chem. 276:10589-93
131. 11]SP analogues*. J. Biol. Chem. 274:23770-76
132. Vassart G, Pardo L, Costagliola S. 2004. A molecular dissection of the glycoprotein hormone receptors. Trends Biochem. Sci. 29:119-26
133. Vassart G. 2004. Activating mutations of the TSH receptor. Thyroid 14:86-87
134. Holst B, Schwartz TW. 2003. Molecular mechanism of agonism and inverse agonism in the melanocortin receptors: Zn(2+) as a structural and functional probe. Ann. NY Acad. Sci. 994:1-11
135. Holst B, Cygankiewicz A, Halkjar JT, Ankersen M, Schwartz TW. 2003. High constitutive signaling of the Ghrelin receptor identification of a potent inverse agonist. Mol. Endocrinol. 17:2201-10
136. Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z. 2004. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279(34):36013-21
137. Borhan B, Souto ML, Imai H, Shichida Y, Nakanishi K. 2000. Movement of retinal along the visual transduction path. Science 288:2209-12
138. Spooner PJ, Sharpies JM, Goodall SC, Bovee-Geurts PH, Verhoeven MA, et al. 2004. The ring of the rhodopsin chromophore in a hydrophobic activation switch within the binding pocket. J. Mol. Biol. 343:719-30
139. Fujimoto Y, Ishihara J, Maki S, Fujioka N, Wang T, et al. 2001. On the bioactive conformation of the rhodopsin chromophore: absolute sense of twist around the 6-s-cis bond. Chemistry 7:4198-204
140. Ebrey TG, Kumauchi M. 2005. Does the chromophore's ring move after photoexcitation of Rhodopsin? Biophys. J. 88:L41-42
141. Del CR, Molinari P, Sbraccia M, Ambrosio C, Costa T. 2004. "Induced-fit" mechanism for catecholamine binding to the beta2-adrenergic receptor. Mol. Pharmacol 66:356-63
142. Kobilka B. 2004. Agonist binding: a multistep process. Mol. Pharmacol. 65:1060-62
143. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK. 2004. Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J. Biol. Chem. 279:686-91
144. Liapakis G, Chan WC, Papadokostaki M, Javitch JA. 2004. Synergistic contributions of the functional groups of epinephrine to its affinity and efficacy at the beta2 adrenergic receptor. Mol. Pharmacol. 65:1181-90
145. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, et al. 2005. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J. Biol. Chem. 280:22165-71
146. Suryanarayana S, Daunt DA, Zastrow Mv, Kobilka BK. 1991. A point mutation in the seventh hydrophobic domain of the α2 adrenergic receptor increases its affinity for a family of β receptor antagonists. J. Biol. Chem. 266:15488-92
147. Rosenkilde MM, Andersen M, Frimurer TM, Schwartz TW. 2005. 7TM receptor activation mechanism-super-agonism through metal-ion site anchoring of aromatic chelators in the TM-III-IV-V pocket. Nat. Struct. Mol. Biol. Submitted
148. Monod J, Wyman J, Changeux JP. 1965. On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12:88-118
149. Seifert R, Wenzel-Seifert K. 2002. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366:381-416
150. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwanz TW. 2004. Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem. 279:53806-17
151. He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, et al. 2004. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429:188-93
152. Alla SA, Quitterer U, Grigoriev S, Maidhof A, Haasemann M, et al. 1996. Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antobodies. J. Biol. Chem. 271:1748-55
153. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson Å, Hoebeke J. 1994. Autoimmunity in idiopathic dilated cardiomyopathy. Circulation 89:2760-67
154. 1-adrenergic receptors in patients with malignant hypertension. Lancet 344:1660-64
155. Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR. 1996. Thrombm receptor activating mutations. J. Biol. Chem. 271:702-6
156. Schwarz MK, Wells TN. 1999. Interfering with chemokine networks-the hope for new therapeutics. Curr. Opin. Chem. Biol. 3:407-17
157. Lau EK, Allen S, Hsu AR, Handel TM. 2004. Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins. Adv. Protein Chem. 68:351-91
158. Huang RC, Yu H, Strader CD, Fong TM. 1994. Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. Biochemistry 33:3007-13
159. Rosenkilde MM, Cahir M, Gether U, Hjorth SA, Schwartz TW. 1994. Mutations along transmembrane segment II of the NK-1 receptor affect substance P competition with non-peptide antagonists but not substance P binding. J. Biol. Chem. 269:28160-64
160. Koshland DE Jr, Nemethy G, Filmer D. 1966. Comparison of experimental binding data and theoretical models in proteins containing subunits. Biochemistry 5:365-85
161. Trumpp-Kallmeyer S, Hoflack J, Bruinvels A, Hibert MF. 1992. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsinreceptors. J. Med. Chem. 35:3448-62
162. Hibert MF, Trumpp-Kallmeyer S, Hoflack J, Bruinvels A. 1993. This is not a G protein-coupled receptor. Trends Pharmacol. Sci. 14:7-12
163. Huggins JP, Trumpp-Kallmeyer S, Hibert MF, Hoflack JM, Fanger BO, Jones CR. 1993. Modelling and modification of the binding site of endothelin and other receptors. Eur. J. Pharm. 245:203-14
164. Tsuchiya D, Kunishima N, Kamiya N, Jingami H, Morikawa K. 2002. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc. Natl. Acad. Sci. USA 99:2660-65
165. Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, et al. 2000. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407:971-77
166. Pin JP, Kniazeff J, Binet V, Liu J, Maurel D, et al. 2004. Activation mechanism of the heterodimeric GABA(B) receptor. Biochem. Pharmacol. 68:1565-72
167. Kniazeff J, Bessis AS, Maurel D, Ansanay H, Prezeau L, Pin JP. 2004. Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat. Struct. Mol. Biol. 11:706-13
168. Terrillon S, Bouvier M. 2004. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 5:30-34
169. Bouvier M. 2001. Oligomerization of G-protein-coupled transmitter receptors. Nat. Rev. Neurosci. 2:274-86
170. Springael JY, Urizar E, Parmentier M. 2005. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev. 16:611-23
171. Milligan G. 2001. Oligomerisation of G-protein-coupled receptors. J. Cell Sci. 114:1265-71
172. Berglund MM, Schober DA, Esterman MA, Geblert DR. 2003. Neuropeptide Y Y4 receptor homodimers dissociate upon agonist stimulation. J. Pharmacol. Exp. Ther. 307:1120-26
173. Jingami H, Nakanishi S, Morikawa K. 2003. Structure of the metabotropic glutamate receptor. Curr. Opin. Neurobiol. 13:271-78
174. 173a. Ostrom RS, Post SR, Insel PA. 2000. Stoichiometry and compartmentation in G protein-coupled receptor signaling: implications for therapeutic interventions involving G(s). J. Pharmacol. Exp. Ther. 294(2):407-12
175. Baneres JL, Parello J. 2003. Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. J. Mol. Biol. 329:815-29
176. Filipek S, Krzysko KA, Fotiadis D, Liang Y, Saperstein DA, et al. 2004. A concept for G protein activation by G protein-coupled receptor dimers: the transducin/rhodopsin interface. Photochem. Photobiol. Sci. 3:628-38
177. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, Engel A. 2003. Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J. Biol. Chem. 278:21655-62
178. Overton MC, Chinault SL, Blumer KJ. 2003. Oligomerization, biogenesis, and signaling is promoted by a glycophorin A-like dimerization motif in transmembrane domain 1 of a yeast G protein-coupled receptor. J. Biol. Chem. 278:49369-77
179. Guo W, Shi L, Javitch JA. 2003. The fourth transmembrane segment forms the interface of the dopamine D2 receptor homodimer. J. Biol. Chem. 278:4385-88
180. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, et al. 1998. A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J. Biol. Chem. 271:16384-92
181. Filizola M, Weinstein H. 2005. The study of G-protein coupled receptor oligomerization with computational modeling and bioinformatics. FEBS J. 272:2926-38
182. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, Parmentier M. 2005. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 67:460-69
183. Urizar E, Montanelli L, Loy T, Bonomi M, Swillens S, et al. 2005. Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO J. 24:1954-64
184. Holst B, Brandt E, Bach A, Heding A, Schwartz TW. 2005. Non-peptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling. Mol. Endocrinol. 19:2400-11
185. Schwartz TW, Holst B. 2005. Agoallosteric modulation and other types of allostery in 7TM receptors. Mol. Pharmacol. In press
186. Hlavackova V, Goudet C, Kniazeff J, Zikova A, Maurel D, et al. 2005. Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J. 24:499-509